Trial reportClinical rheumatology2007
The effect of calcitonin on beta-endorphin levels in postmenopausal osteoporotic patients with back pain.
Trial report in Clinical rheumatology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00754884 (Phase IV Study of Nasal Salmon Calcitonin in the Treatment of Symptoms and Signs of Fibromyalgia), which is not on this map. Cited by 13 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase IV Study of Nasal Salmon Calcitonin in the Treatment of Symptoms and Signs of Fibromyalgia
Who cites it
13 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pooled it
- Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures: a systematic review and meta-analysis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2012Pooled it
- Injection therapy for subacute and chronic low-back pain.The Cochrane database of systematic reviews · 2008Pooled it
- Additive effect of elcatonin to risedronate for chronic back pain and quality of life in postmenopausal women with osteoporosis: a randomized controlled trial.Journal of bone and mineral metabolism · 2015Trial
- Inhalation therapy of calcitonin relieves osteoarthritis of the knee.Journal of Korean medical science · 2012Trial
- Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2011Trial
- Association between vitamin D and zoledronate-induced acute-phase response fever risk in osteoporotic patients.Frontiers in endocrinology · 2022Article
- Spinal Compression Fracture Management: A Review of Current Treatment Strategies and Possible Future Avenues.Global spine journal · 2017Review
- Pathomechanisms and management of osteoporotic pain with no traumatic evidence.Spine surgery and related research · 2017Review
- Effect of Nasal Calcitonin on the Health-Related Quality of Life in Postmenopause Women Affected With Low Bone Density.Iranian Red Crescent medical journal · 2015Article
- Oral calcitonin.International journal of women's health · 2012Article
- [Calcitonin as an analgesic agent: review of mechanisms of action and clinical applications].Brazilian journal of anesthesiology (Elsevier)Review
- Pica in an eating disordered woman with multiple sclerosis: impulse dys-control, compulsive symptom or self-medication attempt?Eating and weight disorders : EWDArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this study was to evaluate the efficacy of calcitonin on beta-endorphin levels in female patients experiencing back pain associated with postmenopausal osteoporosis. The secondary purpose was to assess the pain and quality of life in these patients. There were 30 patients with a mean age of 58.2+/-5.4 years in the treatment group and 26 patients with a mean age of 58.8+/-5.2 years in the placebo group in this randomized, placebo-controlled study. The patients subcutaneously received 100 IU salmon calcitonin or placebo injections and 1,000 mg elementary calcium for 2 weeks. Baseline plasma beta-endorphin levels were measured and repeated after 2 weeks. Patients' pain and quality of life (QOL) were evaluated by using the Visual Analogue Scale, Modified Face Scale, Beck Depression Index, and Nottingham Health Profile. Patients' global assessment of disease activity was also performed at baseline and at the end of the first and second week. We found that plasma beta-endorphin levels in the treatment group were significantly higher than the placebo group at the end of the second week (p<0.001). Although pain and QOL scores were improved at the end of the second week in both groups (p<0.05), the improvement in the treatment group was more significant when compared with the placebo group (p<0.05). Therefore, calcitonin is an analgesic agent, as it increases the plasma beta-endorphin levels in patients with postmenopausal osteoporosis, which consequently improves QOL.
Indexed as
Identifiers
16575494What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.